Mental Health Clinics in Hunlock Creek, PA Accepting Medicare
1 Mental Health Clinics found. Showing 1 - 1
 Green Phoenix Behavioral Health Services Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 2182 State Route 29 Hwy, Hunlock Creek, PA 18621 Phone: 570-239-8052 |
News Archive
Inhibiting MET signaling in glioblastoma has major therapeutic value
A recent discovery by Van Andel Research Institute (VARI) scientists enables the prediction of patient sensitivity to proposed drug therapies for glioblastoma - the most common and most aggressive malignant brain tumor in humans.
Young children's defiance toward mothers may be part of health development
At very young ages, children's defiant behavior toward their mothers may not be a bad thing.
Research findings could pave way for synthesis of biologically active oligopeptides
The research community and pharmaceutical industry have had a long-standing interest in developing peptide-based therapeutics owing to their high target specificity, potent activity, and small size relative to protein-based biologics.
No safe level of caffeine consumption for pregnant women
A new study shows that caffeine consumption by pregnant mothers could harm the fetus and baby. The new study titled, "Maternal caffeine consumption and pregnancy outcomes: a narrative review with implications for advice to mothers and mothers-to-be," was published in the latest issue of the journal British Medical Journal Evidence Based Medicine.
Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
› Verified 5 days ago